KFA Private Wealth Group LLC Buys 164 Shares of Johnson & Johnson (NYSE:JNJ)

KFA Private Wealth Group LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,249 shares of the company’s stock after purchasing an additional 164 shares during the period. KFA Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $979,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. LaFleur & Godfrey LLC increased its position in shares of Johnson & Johnson by 4.9% during the third quarter. LaFleur & Godfrey LLC now owns 118,918 shares of the company’s stock worth $18,521,000 after acquiring an additional 5,585 shares in the last quarter. Hanlon Investment Management Inc. increased its position in shares of Johnson & Johnson by 46.3% during the third quarter. Hanlon Investment Management Inc. now owns 2,081 shares of the company’s stock worth $324,000 after acquiring an additional 659 shares in the last quarter. Kessler Investment Group LLC increased its position in shares of Johnson & Johnson by 1.9% during the third quarter. Kessler Investment Group LLC now owns 52,455 shares of the company’s stock worth $8,170,000 after acquiring an additional 974 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of Johnson & Johnson by 1.5% during the third quarter. Proficio Capital Partners LLC now owns 21,097 shares of the company’s stock worth $3,286,000 after acquiring an additional 306 shares in the last quarter. Finally, Capital Advisory Group Advisory Services LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth about $1,260,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 1.5 %

JNJ opened at $144.61 on Wednesday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock has a market cap of $348.48 billion, a price-to-earnings ratio of 9.02, a PEG ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company’s 50-day moving average price is $154.80 and its two-hundred day moving average price is $155.14.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.68 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 29.68%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, April 15th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.